title: Flexible treatment of gestational diabetes modulated on ultrasound evaluation of intrauterine growth: a controlled randomized clinical trial.
abstract: In order to prevent abnormalities of fetal growth still characterizing pregnancies complicated by Gestational Diabetes (GDM), in the present study we evaluated a therapeutic strategy for GDM based on ultrasound (US) measurement of fetal insulin-sensitive tissues.
  
  
  
  All GDM women diagnosed before 28th week immediately started diet and self-monitoring of blood glucose; after 2 weeks they were randomized to conventional (C) or modified (M) management. In C the glycemic target (GT) was fixed at 90 fasting/120 post-prandial mg/dl; in M GT varied, according to US measurement of the Abdominal Circumference (AC) centile performed every 2 weeks: 80/100 if AC > or =75th, 100/140 if AC<75th. Therapy was tailored to mean fasting (FG) and postprandial glycemia (PPG).
  
  
  
  Globally, 229 women completed the study, 78 in C, 151 in M. Use of insulin was 16.7% in C, 30.4% in M (total groups), significantly more frequent in M than in C (59.7% vs 15.4%) when considering only women with AC > or =75th c. Mean metabolic data were similar in the 2 groups, but in M a tightly-optimized subgroup, resulting from the lowering of GT due to AC > or =75th, coexisted with a less-controlled one, whose higher GT was justified by AC<75th. Pregnancy outcome was better in M, with lower (p<0.05*) rate of LGA* (7.9% vs 17.9%), SGA (6.0% vs 9.0%) and Macrosomia* (3.3% vs 11.5%).
  
  
  
  Our data show the value of a flexible US-based approach to the treatment of GDM. This model does not necessarily involve a generalized aggressive treatment, allowing to concentrate therapeutical efforts on a small subgroup of women showing indirect US evidence of fetal hyperinsulinization. Such a selective approach allowed to obtain a near-normalization of fetal growth, with clear advantages on global pregnancy outcome.
authors.affiliation: Diabetes Unit, Interdisciplinary Diabetes and Pregnancy Center, Niguarda Ca' Granda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy. diabetologia@ospedaleniguarda.it
authors.forename: M
authors.initials: M
authors.lastname: Bonomo
authors.forename: I
authors.initials: I
authors.lastname: Cetin
authors.forename: M P
authors.initials: MP
authors.lastname: Pisoni
authors.forename: D
authors.initials: D
authors.lastname: Faden
authors.forename: E
authors.initials: E
authors.lastname: Mion
authors.forename: E
authors.initials: E
authors.lastname: Taricco
authors.forename: M
authors.initials: M
authors.lastname: Nobile de Santis
authors.forename: T
authors.initials: T
authors.lastname: Radaelli
authors.forename: G
authors.initials: G
authors.lastname: Motta
authors.forename: M
authors.initials: M
authors.lastname: Costa
authors.forename: L
authors.initials: L
authors.lastname: Solerte
authors.forename: A
authors.initials: A
authors.lastname: Morabito
mesh_terms: D000328:Adult; D016640:Diabetes, Gestational / Q000628:therapy*; D005314:Embryonic and Fetal Development / Q000502:physiology*; D005260:Female; D005865:Gestational Age; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D007328:Insulin / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011262:Pregnancy Trimester, Second; D016216:Ultrasonography, Prenatal; D015430:Weight Gain
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin